Omalizumab biosimilar (Glenmark)
奥马佐单抗生物类似药 (Glenmark)
Report date: 2022/06/08 13:46:06
Base Information
Drug NameOmalizumab biosimilar (Glenmark)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A
Develop Information
Active CompaniesGlenmark Pharmaceuticals Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A